8 completed, 1 terminated. 9 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 8, Terminated 1 |
| Phase 1 | 3 | Completed 3 |
Follow IVA: new trials by email Literature Review of IVA trials Research Report on IVA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF) VX-522 mRNA therapy, IVA - Cystic Fibrosis | Phase 1 / Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 26 | 2023-02-27 | 2026-10-09 |
| A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis VX-121, TEZ, VX-561 - Cystic Fibrosis | Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 87 | 2019-04-30 | 2023-04-20 |
| A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis VX-561, IVA, Placebo - Cystic Fibrosis | Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 77 | 2019-04-17 | 2022-01-25 |
| Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis Placebo (matched to VX-121 suspension), VX-121 (Suspension), TEZ/IVA - Cystic Fibrosis | Phase 1 / Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 115 | 2018-03-20 | 2022-07-14 |
| A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis VX-659, TEZ/IVA, IVA - Cystic Fibrosis | Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 124 | 2017-08-08 | 2021-04-22 |
| A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis IVA, TEZ/IVA, VX-445 - Cystic Fibrosis | Phase 1 / Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 225 | 2017-01-23 | 2022-01-18 |
| Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating Mutations VX-561, Placebo, IVA - Cystic Fibrosis | Phase 2 | Terminated | Vertex Pharmaceuticals Incorporated | 11 | 2016-12-01 | 2020-08-26 |
| A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis VX-152, TEZ/IVA, IVA - Cystic Fibrosis | Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 80 | 2016-11-01 | 2021-01-28 |
| A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis TEZ, IVA, VX-440 - Cystic Fibrosis | Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 74 | 2016-10-01 | 2020-08-28 |
Cystic Fibrosis (9)
Vertex Pharmaceuticals Incorporated (9)
United States (8) · United Kingdom (6) · Australia (4) · Belgium (4) · Germany (4) · Netherlands (4) · Canada (2) · Ireland (2) · Austria (1) · Denmark (1) · Israel (1) · Italy (1) · Portugal (1) · Spain (1) · Sweden (1)
PMID 33331662, PMID 36842446, PMID 37983082, PMID 30334692, PMID 30334693
2016 (2), 2018 (2), 2017 (1), 2023 (1)